Peptide therapeutics in pancreatology

Close metadata

Recommended articles:

Methods of pancreatic fibrosis assessment. Russian Journal of Evidence-Based Gastroenterology. 2024;(1):48-57

Opioid peptides in the regulation of eating behavior and appetite. (A Narrative Review). Russian Journal of Evidence-Based Gastroenterology. 2024;(1):79-85

Direct transfistulous ultrasound in minimally invasive surgical treatment of infected pancreatic necrosis. Pirogov Russian Journal of Surgery. 2024;(4):38-43

Minimally invasive surgical treatment of acute necrotic collections without a progressive exudative component in patients with purulent-necrotic parapancreatitis. Endoscopic Surgery. 2024;(2):12-18

Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papillary mucinous tumor associated with ductal adenocarcinoma of the pancreatic tail. Pirogov Russian Journal of Surgery. 2024;(8):57-63

Robotic enucleation of pancreatic insulinoma. Pirogov Russian Journal of Surgery. 2024;(8):64-68

Forensic toxicological characteristics of modern occupational injuries. Forensic Medical Expertise. 2024;(4):58-64

Solid pseudopapillary tumor of the pancreas. P.A. Herzen Journal of Oncology. 2024;(5):50-53

Pancreatic disease management using peptide drugs is reviewed in the article. Somatostatin, octreotide and synthetic analogue of leucine — enkephalin dalargin are under precise attention. Despite various studies of therapeutic effect of these drugs in acute pancreatitis and pancreatic necrosis, their effectiveness is still unclear due to absent works performed according to criteria of evidence-based medicine. It is reported about new medicine «Daloctin P» that is a combination of octreotide and dalargin.

Keywords:

pancreas

diseases

drugs

peptides

Authors:

Bulgakov S.A.

State budgetary educational institution of higher professional education «N.I. Pirogov Russian National Research Medical University», Russian Ministry of Health, Moscow, Russia

List of references:

Heinrich S, Schafer V, Rousson V, Clavien P.A. Evidence — based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243:154-168. https://doi.org/10.1097/01.sla.0000197334.58374.70
Gel’fand BR, Burnevich SZ, Grojzik KL. Preparaty somatostatina v neotlozhnoj pankreatologii: sostojanie i perspektiva. Vestnik intensivnoj terapii. 1998;3:19-24. (In Russ.)
Smagin VG, Vinogradov VA, Bulgakov SA. Ligandy opiatnyh receptorov. M.: Nauka, 1983;270. (In Russ.)
Limberg K, Kommerell B. Treatment of acute pancreatitis with somatostatin. New Eng J Med. 1980;79:284.
Choi TK, Mok F, Zhan W, Fan ST, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomized controlled trial. Gut. 1989;30:223-227. https://doi.org/10.1136/gut.30.2.223
Usadel KH, Uberla KK, Leuschner U. Treatment of acute pancreatitis with somatostatin: results of the multicenter double-blind trial (APTS). Dig Dis Sci.1985;30 A 992.
McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol. 1997;21:13-19.
Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomized, double blind, multicenter trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45:97-104. https://doi.org/10.1136/gut.45.1.97
Uhl W, Warshaw A, Imrie C. IAP Guidelines for the surgical management of acute pancreatitis. Pancreatology. 2002;2:565-573. https://doi.org/10.1159/000067684
Vinogradov VA, Smagin VG, Titov MI. Sinteticheskie peptidy kak lekarstvennye veshhestva. Nejropeptidy v jeksperimental. i klinich. praktike. M. 1986;3-7. (In Russ.)
Bulgakov SA. Agonisty opiatnyh receptorov v gastrojenterologicheskoj praktike. Dokazatel’naja gastrojenterologiya. 2015;4(1):14-18. (In Russ.) https://doi.org/10.17116/dokgastro201541-214-18
Il’inskij OB, Spevak SE, Shekhter AB. Novyj peptidnyj aktivator reparativnoj regeneracii tkanej. Farmakol.i toksikol. 1987;4:64-66. (In Russ.)
Bulgakov SA. Dalargin v gastrojenterologii. M. 2008. (In Russ.)
Georgadze AK, Permjakov NK, Penin VA, et al. Jeffektivnost’ dalargina v kompleksnom lechenii bol’nyh s razlichnymi formami ostrogo pankreatita. Nejropeptidy: ih rol’ v fiziologii i patologii. Tomsk. 1985;167-168. (In Russ.)
Vasil’ev RKh, Stanulis AI, Osadchaya LV, Panphilov SA, Kaminskij NV. Lazery i nejropeptidy v lechenii sochetannyh zabolevanij zheludka, dvenadcatiperstnoj kishki i podzheludochnoj zhelezy. Aktual’nye voprosy lazernoj meditsiny. M. 1991;88-89. (In Russ.)
Grigus YaI, Mikhajlova OD, Bulychyov VF, Gorbunov AYu. Otsenka jeffektivnosti dalargina v lechenii postgastrorezekcionnogo pankreatita. Prakticheskaja meditsina. 2012;3:78-82. (In Russ.)
Voskanjan SJe, Korsakov IN, Najdyonov EV. Profilaktika ostrogo posleoperatsionnogo pankreatita v khirurgii raka podzheludochnoj zhelezy. Gepatol. 2013;2:95. (In Russ.)
Onopriev VI, Voskanyan SJe, Korsakov IN. Prophilaktika ostrogo posleoperatsionnogo pankreatita posle radikal’noj duodenoplastiki. Kubanskij nauch med vestnik. 2006;7-8:107-115. (In Russ.)
Krylov NN, Egorov AV, Latiphova LV, Vychuzhanin DV. Kliniko-jekonomicheskie aspekty medikamentoznoj profilaktiki ostrogo posleoperacionnogo pankreatita. Vesti hirurg gastrojenterol. 2011;1:10. (In Russ.)
Bulgakov SA. Dalargin v pankreatologii. Ros zhurnal gastrojenterologii, gepatologii, koloproktologii. 2009;5:67. (In Russ.)
Minushkin ON, Maslovskij LV. Jetiologicheskie aspekty terapii hronicheskih pankreatitov. Consilium medicum. 2005;6:444-447. (In Russ.)
Korobov NV. Otechestvennye innovacionnye lekarstvennye sredstva: mesto dalargina v lechenii ostrogo pankreatita. Vedomosti nauchnogo tsentra jekspertizy sredstv meditsinskogo primeneniya. 2007;4:93-98. (In Russ.)
Bespalova ZhD, Ovchinikov MV, Chertorizhskij EA, Yasnetsov VV, Ivanov YuV. Patent RF na izobretenie №RU 2341282/24.0.2007. Farmacevticheskaja kompozicija, obladajushhaja pankreatotropnoj aktivnost’ju, i sposob poluchenija farmacevticheskoj kompozicii. (In Russ.)

Close metadata